293 related articles for article (PubMed ID: 7994190)
1. Effects of two novel bisphosphonates on bone cells in vitro.
Evans CE; Braidman IP
Bone Miner; 1994 Aug; 26(2):95-107. PubMed ID: 7994190
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts.
Reinholz GG; Getz B; Pederson L; Sanders ES; Subramaniam M; Ingle JN; Spelsberg TC
Cancer Res; 2000 Nov; 60(21):6001-7. PubMed ID: 11085520
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
4. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
5. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
[TBL] [Abstract][Full Text] [Related]
6. Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro.
Idris AI; Rojas J; Greig IR; Van't Hof RJ; Ralston SH
Calcif Tissue Int; 2008 Mar; 82(3):191-201. PubMed ID: 18259679
[TBL] [Abstract][Full Text] [Related]
7. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Vitté C; Fleisch H; Guenther HL
Endocrinology; 1996 Jun; 137(6):2324-33. PubMed ID: 8641182
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.
Flanagan AM; Chambers TJ
Calcif Tissue Int; 1991 Dec; 49(6):407-15. PubMed ID: 1840176
[TBL] [Abstract][Full Text] [Related]
10. Influence of bisphosphonates on the osteoblast RANKL and OPG gene expression in vitro.
Koch FP; Merkel C; Ziebart T; Smeets R; Walter C; Al-Nawas B
Clin Oral Investig; 2012 Feb; 16(1):79-86. PubMed ID: 20938793
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts.
Fromigué O; Body JJ
J Endocrinol Invest; 2002 Jun; 25(6):539-46. PubMed ID: 12109626
[TBL] [Abstract][Full Text] [Related]
12. Breast carcinomas synthesize factors which influence osteoblast-like cells independently of osteoclasts in vitro.
Evans CE; Ward C; Braidman IP
J Endocrinol; 1991 Feb; 128(2):R5-8. PubMed ID: 2005408
[TBL] [Abstract][Full Text] [Related]
13. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
Lipton A; Small E; Saad F; Gleason D; Gordon D; Smith M; Rosen L; Kowalski MO; Reitsma D; Seaman J
Cancer Invest; 2002; 20 Suppl 2():45-54. PubMed ID: 12442349
[TBL] [Abstract][Full Text] [Related]
14. Osteoclast recruitment in mice is stimulated by (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate.
Marshall MJ; Holt I; Davie MW
Calcif Tissue Int; 1993 Jan; 52(1):21-5. PubMed ID: 8453501
[TBL] [Abstract][Full Text] [Related]
15. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts.
Selander K; Lehenkari P; Väänänen HK
Calcif Tissue Int; 1994 Nov; 55(5):368-75. PubMed ID: 7532540
[TBL] [Abstract][Full Text] [Related]
16. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro.
Schindeler A; Little DG
Biochem Biophys Res Commun; 2005 Dec; 338(2):710-6. PubMed ID: 16243296
[TBL] [Abstract][Full Text] [Related]
17. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound.
Green JR; Müller K; Jaeggi KA
J Bone Miner Res; 1994 May; 9(5):745-51. PubMed ID: 8053405
[TBL] [Abstract][Full Text] [Related]
19. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment.
Mundy GR; Yoneda T; Hiraga T
Semin Oncol; 2001 Apr; 28(2 Suppl 6):35-44. PubMed ID: 11346863
[TBL] [Abstract][Full Text] [Related]
20. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
Yu X; Schøller J; Foged NT
Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
